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ARC1172 is a 41-mer DNA aptamer selected to bind
the A1 domain of von Willebrand factor (VWF). A
derivative of ARC1172 with modifications to increase
intravascular survival inhibits carotid artery throm-
bosis in a Cynomolgus macaque model and inhibits
VWF-dependent platelet aggregation in humans,
suggesting that such aptamers may be useful to
prevent or treat thrombosis. In the crystal structure
of a VWF A1-ARC1172 complex, the aptamer adopts
a three-stem structure of mainly B-form DNA with
three noncanonical base pairs and 9 unpaired resi-
dues, 6 of which are stabilized by base-base or
base-deoxyribose stacking interactions. The ap-
tamer-protein interface is characterized by cation-p
interactions involving Arg, Lys, and Gln residues,
often stabilized by H-bonds with adjacent bases.
The ARC1172 binding site on the A1 domain overlaps
with that of botrocetin and clashes with glycoprotein
Iba binding at an adjacent site, which accounts for
the antithrombotic activity of ARC1172 and related
aptamers.
INTRODUCTION
Aptamers are RNA or DNA oligonucleotides that bind specific
target molecules, identified by selection in vitro from large
random sequence libraries (termed SELEX: systematic evolution
of ligands by exponential enrichment) (Ellington and Szostak,
1990; Tuerk and Gold, 1990). Many structures illustrate how
proteins have evolved to recognize nucleic acids. However,
few structures are available to show how aptamers can adopt
complex conformations that enable specific, high-affinity
binding to proteins that do not normally interact with nucleic
acids.
Several properties of aptamers make them an attractive class
of therapeutic compounds. For example, aptamers can be
isolated that bind many proteins with dissociation constants in
the low-nanomolar range. Aptamers have little immunogenicity,
and simple structural modifications can adjust their bioavail-1476 Structure 17, 1476–1484, November 11, 2009 ª2009 Elsevierability or pharmacokinetics. In addition, complementary oligonu-
cleotide antidotes can acutely reverse the effects of aptamers,
permitting control over their activity in vivo. Aptamers have
been developed against proteins involved in infectious diseases,
cancer, and cardiovascular diseases (Keefe and Schaub, 2008;
Nimjee et al., 2005). One aptamer that targets vascular endothe-
lial growth factor (VEGF) (pegaptinic sodium,Macugen) has been
approved for therapy of age-related macular degeneration
(Ng et al., 2006).
Von Willebrand factor (VWF) is a giant multimeric plasma
protein that plays an essential role in tethering platelets to the
injured vessel wall. This process is mediated by interactions
between domain A1 of VWF subunits and platelet-receptor
glycoprotein Iba (GPIba) on the platelet surface (Sadler, 1998),
and aptamers have been devised that block this interaction.
For example, SELEX applied to a combinatorial library identified
a 40-mer RNA that bound to VWF with a Kd < 20 nM and also
blocked VWF-dependent platelet interactions in vitro (Oney
et al., 2007). A similar approach was used to select a modified
41-mer DNA aptamer, ARC1172, that binds with high affinity to
the VWF A1 domain and blocks VWF binding to GPIba (Diener
et al., 2009; Gilbert et al., 2007). ARC1779 was derived from
ARC1172 (Figure 1A; see Figure S1 available online) by adding
modifications to prevent digestion by nucleases while preserving
the same affinity for the VWF A1 domain. When given intrave-
nously to human volunteers and assayed ex vivo, ARC1779
dose-dependently inhibits VWF activity and prolongs the PFA-
100 closure time with EC90 values of 2–3 mg/ml (Diener et al.,
2009; Gilbert et al., 2007). ARC1779 also inhibits thrombus
formation on injured porcine arteries ex vivo, and blocks carotid
artery thrombosis induced by electrical injury in nonhuman
primates (Diener et al., 2009; Keefe and Schaub, 2008). These
properties suggest that ARC1779 may be useful to prevent or
treat VWF and platelet-dependent thrombosis in acute coronary
syndromes, percutaneous coronary intervention procedures, or
thrombotic thrombocytopenic purpura (Diener et al., 2009;
Gilbert et al., 2007). To characterize this aptamer-protein interac-
tion, we have determined the crystal structure of a complex
between recombinant VWF domain A1 and ARC1172. The
extensive aptamer-protein interface is characterized by several
cation-p interactions and overlaps the GPIba binding site, which
accounts for the antithrombotic activity of ARC1172 and related
aptamers.Ltd All rights reserved
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Structure of VWF A1 in Complex with a DNA AptamerRESULTS
Overall Structure of ARC1172 in Complex with VWF A1
Aptamer ARC1172 was crystallized with the VWF A1 domain
(residuesGlu497-Thr705,mature VWF subunit numbering) under
two different conditions. The crystals belonged to the space
groups P212121 (structure I) and P21212 (structure II) and dif-
fracted to a resolution of 2.4 A˚ and 2.7 A˚, respectively (Table 1).
The model for structure I was built for VWF A1 domain residues
Phe507-Thr705 and for aptamer residues G1-C40 with well-
defined density, except for the T14-C16 loop of the aptamer
(see Figure S2). However, this loop was clearly seen in the
density map for structure II (Figure S3), which also showed 5
more residues at the N terminus of the VWF A1 domain
(Pro502-Asp506) and C41 at the 30 end of the aptamer, but
lacked residues Pro703-Thr705 at the C terminus of the VWF
A1 domain. Aside from these differences, which are due to differ-
ences in packing between the two crystal environments, both
structures are very similar, with a root-mean-square deviation
(rmsd) of 1.461 A˚ (normalized rmsd [Carugo and Pongor, 2001]
of 0.713 A˚) for the nucleotides 1–40 (Figure S4). Neither structure
had density for the 30-terminal inverted T, suggesting it is disor-
dered.
The VWF A1 domain bound to ARC1172 has essentially the
same structure (Figure 1B and Figure S5) as observed previously
for the A1 domain in isolation (Emsley et al., 1998) or bound to
GPIba (Dumas et al., 2004; Huizinga et al., 2002), botrocetin (Fu-
kuda et al., 2002), bitiscetin (Maita et al., 2003), or Fab NMC-4
(Celikel et al., 1998), which consists of a central 6-strand b sheet
Figure 1. Structure of Aptamer ARC1172 in Complex with VWF A1
Domain
(A) Nucleotide sequence of ARC1172. Yellow shading indicates the nucleo-
tides that contact the VWF A1 domain; squares below the sequence identify
nucleotides in the consensus sequence that are required for high-affinity
binding to VWF; triangles indicate nucleotides that do not tolerate 20-O-methyl
modification (Diener and Lagasse´, 2006).
(B) Cartoon representation based on the space group P212121 structure. The
a helices (Arabic) and b strands (Roman) within the VWF A1 domain are
numbered. Nucleotides within 4.2 A˚ of the VWF A1 domain are colored yellow;
nucleotides involved in noncanonical base pairs are labeled and shown by ball
and stick.
(C) Ball-and-stick representation of noncanonical base pairs and their
composite omit electronic density map at a contour level of 1.0 s. The dashed
lines in cyan indicate hydrogen bonds.
Table 1. X-Ray Diffraction Data and Model Refinement Statistics
Structure I (3HXO) II (3HXQ)
Data Collection
Space group P212121 P21212
Cell dimensions




Resolution (A˚) 30-2.40 (2.49-2.4)a 38-2.69 (2.8-2.69)
Number of reflections 14563 9819
Completeness (%) 94.9 (86.3) 94.8 (83.9)
Data redundancy 6.0 (2.6) 6.4 (4.0)
Rmerge (%) 6.4 (31.3) 8.0 (31.6)
I/s 20.2 (2.6) 17.2 (2.8)
Refinement
Resolution range (A˚) 25-2.40 (2.59-2.40) 38-2.69 (3.08-2.69)
Rwork (%)
b 22.82 (35.90) 22.06 (29.35)
Rfree (%)
b 27.37 (37.66) 27.88 (35.27)
No. non-hydrogen atoms 2464 2451
No. water molecules 177 102
Ramachandran plot
(% residues)c
Most favored/additional 86.1/12.8 83.2/16.3
Generous/disallowed 1.1/0 0.5/0
Rmsd
Bond lengths (A˚) 0.002 0.003




aNumbers in parentheses are for the highest-resolution shell.
b Phenix.
c Procheck (Laskowski et al., 1993).
dMaximum likelihood-based error calculated by Phenix.Structure 17, 1476–1484, November 11, 2009 ª2009 Elsevier Ltd All rights reserved 1477
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Structure of VWF A1 in Complex with a DNA Aptamercore (antiparallel strand b3 and parallel strands b1,2 and 4-6) en-
compassed by 7 peripheral a helixes (helix a1-7) (Figure 1B and
Figure S5). Therefore, aptamer binding doesn’t substantially
alter the conformation of the VWF A1 domain.
ARC1172 consists of three helical duplex stems and two
hairpin loops (Figures 1B and 2). Nucleotides C32-C41 interact
with segments G23-G26 and G1-G6 to form a B-type helix inter-
rupted by a stem-loop comprised of residues C7-T22. Stem I
consists of standard Watson-Crick base pairs between the 50
and 30 ends of the aptamer. Stem III consists of 4 base pairs
between segments G23-G26 and C32-T35, a mismatched
base pair (T27 and T31), and a single-residue GCC loop (Chin
and Chou, 2003). Stem II is another B-type helix consisting of 5
base pairs between segments A8-C13 and G17-G21, with T10
exposed as a single residue bulge. The proximal end of stem II
abuts a mismatched internal loop comprised of C7 and T22. In
structure I, the distal end of stem II is capped by a typical pyrim-
idine-rich tri-loop (T14-C16) in which T15 stacks with C13 and
the base of T14 inserts into the minor groove of the adjacent
stem to interact with the deoxyribose of C13. (Chou et al.,
2003) This tri-loop adopts a different conformation in structure
II because of close crystal contacts, so that T14 is some distance
away from the minor groove and T15 cannot stack with C13
(Figures S2 and S3).
The aptamer contains just three noncanonical base pairs
(Figure 1C). At the proximal end of stem II, A8 and G21 form
a sheared GdA pair (Chou et al., 2003) in which G21 is stabilized
by stacking interactions with adjacent C20 and cross-strand
stacking with C7, and A8 is stabilized by stacking with the adja-
cent G9. At the base of stem III, G23 and T35 form a GdT reverse
Figure 2. Diagram Showing the Base Pairing of ARC1172 and Inter-
actions with VWF Domain A1
Watson-Crick and noncanonical base pairs are indicated by adjacent labeled
boxes. Nucleotides in yellow are within 4.2 A˚ of VWF A1. Solid black lines show
hydrogen bonds (Figure S6 and Table S1); solid red lines indicate salt bridges
(Table S2); dashed lines indicate van der Waals interactions.1478 Structure 17, 1476–1484, November 11, 2009 ª2009 Elsevierwobble base pair in which the flipped G23 (syn) locally distorts
the B-DNA structure to accommodate the extrusion of stem II.
In addition, the distal GCC loop of stem III is closed by an unusual
sheared-type G(anti)dC(anti) base pair between G28 and C30. A
sheared G(anti)dC(syn) base pair can close a single nucleotide
GXC loop at the end of a DNA duplex, and the rare syn cytidine
conformation is necessary to preserve the geometry of the adja-
cent Watson-Crick base pair. (Chin and Chou, 2003) In the case
of aptamer ARC1172, the sheared G28(anti)dC30(anti) arrange-
ment is possible only because the adjacent nucleotides (T27
and T31) are not paired (Figure 2). Allowing C30 to retain an
anti conformation requires T31 to rotate away from the helical
axis, where it is stabilized by base stacking with T22. T27
remains in a standard Watson-Crick-like position, stacked
between G26 and G28.
Throughout the aptamer all but 9 nucleotides participate in
base pairing (Figures 1B and 2), and 6 of the unpaired residues
are stabilized by base-base or base-deoxyribose stacking inter-
actions discussed above. Among the remaining three unpaired
bases, C29 and T10 make extensive contacts with the A1
domain. Only C16 is fully exposed to solvent, which may allow
considerable mobility and explain the poor density for this
base in structure II.
The Aptamer-Protein Interface
The extensive interface between ARC1172 and the VWF A1
domain buries a solvent-accessible surface area of 911 A˚2 on
the aptamer and 1166 A˚2 on the protein (Figure 3). The convex
interface on the A1 surface binds to a concave pocket on the
aptamer with striking shape and charge complementarity
(Figure 3). In structure I, the interface of ARC1172 involves 16
bases, 14 of which make a total of 24 H-bonds (Figure S6 and
Table S1) and 4 salt bridges (Table S2) with the A1 domain.
Two unpaired bases that do not participate in base-base stack-
ing interactions are stabilized by contacts with the A1 domain.
T10 extends away from stem II and stacks with the aromatic
ring of Phe603 (Baker and Grant, 2007). C29 protrudes from
the GCC loop at the end of stem III and interacts with 7 amino
acid residues (Gln625, Pro655, His656, Ala657, Asn658,
Leu659, and Lys660) (Figure 2).
Specific protein-DNA recognition often depends on cation-p
interactions between nucleic acid bases and amino acid residues
with full or partial positive charge (Arg, Lys, Asn, Gln) (Rooman
et al., 2002; Wintjens et al., 2000), as well as p-p interactions
for Arg residues (Mao et al., 2003), and the aptamer-A1 interface
contains a remarkable cluster of Arg andGln residues that extend
like fingers into deep cavities in the aptamer (Figure 3). The gua-
nidinium group of Arg632 stacks above A8 (Figure 4A), where it is
stabilized byH-bondswith C7 at the base of stem II; this arrange-
ment comprises a typical cation-p/H-bond stair motif (Rooman
et al., 2002). Immediately adjacent to this p-stair motif, stem III
displays four additional cation-p interactions (Figure 4B).
Arg629 stacks above C24 and H-bonds to G25 in another p-stair
motif.Gln628 is sandwichedbetweenC30andC32 in theposition
of the normal Watson-Crick partner for T27, to which it makes
2 H-bonds. Gln625 is sandwiched between G28 and C29. In
structure I, Lys660 participates in a cation-p interaction with
T31 and is also stabilized by a salt bridge with the phosphate of
T31; however, crystal-packing interactions in structure II displaceLtd All rights reserved
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Structure of VWF A1 in Complex with a DNA Aptamerthe side chain of Lys660 so that it forms a salt bridge with
a symmetry-related aptamer and does not stack with T31. The
amino acid residues involved in these various cation-p interac-
tions account for 65% of the binding interface on the A1 domain,
which is consistent with the importance of this extensive network
to the strong aptamer-A1 interaction (Kd approximately 2 nM)
(Diener et al., 2009).
It is worth noting that the nucleotides of ARC1172 that contact
the A1 domain (C7-T10 and G21-C32) have a significantly lower
normalized rmsd of 0.497 A˚ between the two structures
compared with 0.991 A˚ for other nucleotides (Figure S4). This
difference suggests that specific interaction with the VWF A1
domain stabilizes the binding pocket of the aptamer.
The nucleotides within the binding interface correspond
closely to the consensus nucleic acid sequence required for
high-affinity binding to VWF generated from SELEX (Diener and
Lagasse´, 2006). In addition, the nucleotides in the binding inter-
face do not tolerate replacement by other nucleotides and most
do not allow 20-O-methyl modification without a decrease in
binding (Figure 1A).
Figure 3. Interface between ARC1172 and VWF A1 Domain
(A) Surfaces of VWF A1 (left) and aptamer (right), separated for visualization
and colored by electrostatic potential red (negative) to blue (positive) that
are calculated with APBS (Baker et al., 2001).
(B) Contacting surfaces of VWF A1 (left) and the aptamer (right) separated by
less than 4.2 A˚ are boxed by dashed lines. Stick representations (right) show
the locations of the side chains of Gln628, Arg629, Arg632, and Phe603, which
playmajor roles within the interface. Compared to the views in (A), VWFA1 (left)
and ARC1172 (right) were rotated approximately 90 around the vertical axis
so that the binding interfaces face the viewer.Structure 17, 1476–148Structural Basis for the Antithrombotic Activity
of ARC1172
Thrombus formation is initiated by the binding of VWFA1 domain
to platelet glycoprotein GPIba. The concave face of the GPIba
amino-terminal domain wraps around the convex A1 surface
(Huizinga et al., 2002), but ARC1172 binding overlaps with the
site occupied by GPIba and sterically excludes it (Figure 5).
For example, the thymidine base of T10 projects toward A1 helix
a3 to obstruct residues Lys599 and Phe603, and a deep cavity
on the aptamer surrounds the side chain of Arg632 (Figure 3B);
these amino acid residues contribute to the A1-GPIba interface
(Huizinga et al., 2002). In addition, aptamer residues G9-G11
are predicted to clash with GPIba residues Asp175, Ser195-
Pro198, and Glu225 (Figure 5E and Table S3) (Huizinga et al.,
2002). Interference with A1-GPIba binding accounts for the
ability of ARC1172 (or ARC1779) to block VWF-dependent
platelet aggregation in vitro and in vivo (Diener et al., 2009;
Diener and Lagasse´, 2006).
Botrocetin is a snake venom protein that forms a high-affinity
ternary complex with VWF domain A1 and platelet GPIba
(Andrews et al., 1989; Fukuda et al., 2005), and thereby
promotes VWF-dependent platelet aggregation. ARC1172 and
botrocetin occupy a similar binding surface on the VWF A1
domain (Figures 5A and 5D) (Fukuda et al., 2002), which explains
the inhibition of botrocetin-induced platelet aggregation by
ARC1172 (Diener et al., 2009). Botrocetin binds the VWF A1
domain with a dissociation constant (Kd) of 12 nM (Andrews
et al., 1989), and ARC1172 binds with a Kd of approximately
0.6 nM (Figure 6A).
The binding of VWF to platelet GPIba is potentiated dramati-
cally by fluid shear stress, which appears to shift the VWF A1
domain from a low-affinity to a high-affinity conformation. Mono-
clonal antibody 1C1E7 has a similar effect. The epitope of 1C1E7
is within the D’D3 region of VWF, just N terminal to the A1
domain. 1C1E7 markedly increases the binding of VWF to plate-
lets, apparently by disrupting an inhibitory intramolecular inter-
action between domains D’D3 and A1 (Ulrichts et al., 2006). In
contrast, ARC1172 binds equally well to VWF with or without
fluid shear stress (Figure 6A), and with or without antibody
1C1E7 (Figures 6B and 6C). As expected, ARC1172 binding to
VWF is inhibited by soluble recombinant VWF A1 domain or by
excess ARC1172 (Figure 6D). These results indicate that the
ARC1172 binding site should be fully accessible in circulating
plasma VWF.
DISCUSSION
We have little information about how DNA or RNA aptamers
adapt structurally to bind proteins that do not physiologically
recognize nucleic acids. Only two previous reports describe rele-
vant crystal structures and both involve the same protein,
thrombin. In one case, a small palindromic 15-nucleotide DNA
aptamer d(GGTTGGTGTGGTTGG), C15-mer (Bock et al.,
1992), was bound to thrombin exosite 1, a positively charged
surface that is required for the recognition of several natural
thrombin substrates. In part because of the extreme local
symmetry of this G-quartet arrangement, the precise structure
of the thrombin-C15-mer complex was difficult to determine,
requiring a combination of NMR and X-ray crystallographic4, November 11, 2009 ª2009 Elsevier Ltd All rights reserved 1479
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Structure of VWF A1 in Complex with a DNA AptamerFigure 4. Cation-p Interactions between VWF A1 and ARC1172
(A) Cation-p/H-bond stair motif formed by Arg632 (red/green/blue) and adjacent nucleotides (gray).
(B) Stereo view showing cation-p interactions involving Gln625, Gln628, Arg629, and Lys660 and adjacent nucleotides shown. Atoms of amino acid residues and
nucleotides that are within hydrogen bonding distance are joined by dashed lines (red).approaches (Padmanabhan and Tulinsky, 1996). The C15-mer
aptamer folds into a pair of stacked planar G-quartets connected
by two TT loops at the ends and a TGT loop in the center.
This arrangement is very different from the predominantly helical
structure of ARC1172. Nevertheless, several interactions
between C15-mer and thrombin (Figure S7) are similar to the
cation-p and aromatic interactions between ARC1172 and
VWF A1. For example, thrombin Arg75 stacks with G11 and its
guanidinium group makes an H-bond to O4 of T13. Also,
thrombin Arg77A stacks with G14 and makes an H-bond to O2
ofT13.Bothof these interactionsconstitutecation-p/H-bondstair
motifs (Rooman et al., 2002; Wintjens et al., 2000), not remarked
previously in descriptions of the thrombin-C15-mer structure. In
addition, His71 stacks edgewise with T12, and Tyr76 stacks
parallel to T3; both are similar to aromatic interactions in physio-
logical protein-nucleic acid complexes (Baker and Grant, 2007).
Thrombin has another electropositive surface that interacts
with heparin, termed exosite 2, and recently a structure was
reported for a complex between thrombin and an RNA aptamer,
Toggle-25t, selected to bind to exosite 2 (Long et al., 2008). The
Toggle-25t-thrombin interface is dominated by cation-p interac-
tions involving 2 Arg residues: Arg165 stacks with A15, and Arg
233 stacks between A15 and A7. In addition, the guanidinium
moiety of Arg233 makes an H-bond to O6 of G16, forming a
typical cation-p/H-bond stair motif. These interactions account
for the majority of the Toggle-25t-thrombin interacting surface
(Long et al., 2008).
Thus, despite the substantial differences in composition and
structure of the C15-mer-thrombin, Toggle-25t-thrombin, and
ARC1172-VWF A1 aptamer-protein complexes, they all exhibit
clusters of cation-p interactions that include p-stair motifs stabi-
lized by H-bonds to adjacent bases. Clustered cation-p and1480 Structure 17, 1476–1484, November 11, 2009 ª2009 Elsevier Lp-stair motifs also are common in naturally occurring protein-
nucleic acid complexes (Rooman et al., 2002; Sathyapriya
et al., 2008; Sathyapriya and Vishveshwara, 2004; Wintjens
et al., 2000), and seem particularly suitable for the construction
of highly complementary, interdigitated interfaces that bury rela-
tively large surface areas. Although Gln and Asn residues can
participate in cation-p interactions, positively charged Arg and
Lys are much more frequent (Rooman et al., 2002; Wintjens
et al., 2000). Consequently, aptamers selected in vitro may
generally prefer electropositive protein surfaces, especially
those with clustered basic residues. A selection method to
bias against these interactions may be required to identify
aptamers that bind to other sites.
In the ARC1172-A1 structure, nucleotides interacting directly
with protein are confined to Stem III and the proximal segment
of Stem II (Figure 2), and most of these nucleotides do not
tolerate substitution or modification without loss of binding
affinity. In contrast, almost all nucleotides outside these critical
regions can be replaced provided that any base pairing is
preserved (Diener and Lagasse´, 2006). For example, ARC1779
was derived from ARC1172 by introducing 20-methoxy-ribose
modifications at 26 positions, almost all in stem I and distal
stem II. Additional modifications included deletion of the terminal
base pair from Stem I, introduction of a phosphorothioate
linkage between G21 and T22, and conjugation of 20 kDa poly-
ethylene glycol to the 50-G residue (Figure S1). These differences
do not directly alter any atoms that contact VWF A1 (Figure 2;
Table S1), and both ARC1779 and ARC1172 bind to VWF A1
with similar affinity (Lagasse et al., 2007).
Currently available antithrombotic agents that inhibit blood
clotting (e.g., warfarin, heparin derivatives) or platelet function
(e.g., clopidogrel, aspirin, abciximab), also significantly increasetd All rights reserved
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Structure of VWF A1 in Complex with a DNA AptamerFigure 5. Structural Basis for the Antithrombotic Activity of ARC1172
(A) ARC1172-A1 complex (PDB code: 3XHO) with the surface of A1 domain colored according to negative (red) and positive (blue) electrostatic potential.
(B) The surface of VWF A1 (Phe507-Thr705) within 4.2 A˚ of ARC1172 is colored yellow.
(C) The surface of VWF A1 (PDB code: 1M10) in contact with GPIba is colored magenta. The yellow dashed line encompasses the surface that is in contact with
ARC1172 as in (B).
(D) Surface of VWF A1 domain (Asp498-Thr705) in complex with botrocetin (cyan) and GPIba (magenta) (PDB ID: 1U0N) showing that botrocetin and ARC1172
occupy similar sites. The surfaces of A1 domain in (A) and (D) are slightly different due to small differences in side-chain positions and also to the different length
and orientation of the N-terminal residues at the bottom of the structures.
(E) Stereo view of VWF A1 complexed with ARC1172 (yellow cartoon) and GPIba (magenta, PDB ID: 1M10) would clash upon binding to VWF A1 domain. The
clashing residues are listed in Table S3. The A1 domain has the same orientation in (A, D, and E), and is turned approximately 90 around the vertical axis in (B
and C).the risk of bleeding during treatment. Agents that target the inter-
action of VWFwith GPIba have not been tested extensively in hu-
mans, but may differ in the severity or type of bleeding associ-
ated with their use. For example, markedly decreased VWF
function, as occurs in von Willebrand disease, is characterized
by skin bruising, oral and nasal bleeding, menorrhagia, and
sometimes by gastrointestinal bleeding. Bleeding into muscle,
brain, or other organs is relatively uncommon (Sadler, 1998).
VWF-dependent platelet adhesion is especially important under
conditions of high fluid shear stress that occur normally in arteri-
oles, or pathologically in arteries with stenotic lesions caused by
atherosclerosis. Therefore, a VWF antagonist might inhibit
thrombosis in a high shear subset of the arterial circulation,
leaving hemostasis relatively intact in the venous circulation
where other mechanisms are dominant. In fact, preclinicalStructure 17, 1476–14animal studies show that several agents able to block VWF-
dependent platelet adhesion, by inhibiting VWF or platelet
GPIb, can inhibit arterial thrombosis with minimal prolongation
of skin bleeding times (De Meyer et al., 2008). Similar results
have been reported for ARC1779 in a Cynomolgus macaque
model of carotid artery thrombosis (Diener et al., 2009; Keefe
and Schaub, 2008).
Whether the apparent selectivity of ARC1779 will have clinical
utility in humans remains to be established, but preliminary
results seem encouraging. When added to human blood,
ARC1779 does not inhibit platelet aggregation induced by ADP,
collagen, or arachadonic acid at concentrations (e.g., 10 mg/ml)
that completely bock VWF-dependent platelet function (Spiel
et al., 2009). A phase 1 trial in healthy volunteers (Gilbert et al.,
2007) suggests that ARC1779 is relatively safe for short-term84, November 11, 2009 ª2009 Elsevier Ltd All rights reserved 1481
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Structure of VWF A1 in Complex with a DNA Aptameradministration and does not cause excessive bleeding at
concentrations that block platelet aggregation ex vivo. A recent
case report describes one patient with refractory thrombotic
thrombocytopenic purpurawho received ARC1779 over a period
of 3 weeks, apparently with a reproducible rise in the platelet
count (Knobl et al., 2009). Ongoing and planned phase 2 trials
should determine whether ARC1779 is safe and efficacious for
treating thrombotic thrombocytopenic purpura (NCT00632242,
NCT00726544) or for preventing thromboembolism associated
with carotid endarterectomy (NCT00742612).
EXPERIMENTAL PROCEDURES
Purification, Crystallization, and Data Collection
The VWF A1 domain (VWF amino acid residues Glu497-Thr705, mature
subunit numbering) was expressed in E. coli, refolded and purified as
described previously (Maita et al., 2003) with minor modifications. Briefly,
refolded A1 was adsorbed onto a 5 ml HiTrap-heparin column (GE Healthcare
Life Sciences, Piscataway, NJ) in 10mMTris-HCl (pH 7.4), 150mMNaCl (TBS)
and eluted with a 60 ml linear gradient of 150–500 mM NaCl in TBS. Late
eluting fractions containing A1 were pooled and concentrated by ultrafiltration.
Aggregates were removed by chromatography on a column of Superdex-200
(16/60, GE Healthcare Life Sciences) equilibrated with TBS. Aptamer
ARC1172 was chemically synthesized (IDT DNA Tech., Coralville, IA) and dia-
lyzed against 20 mM HEPES (pH7.4), 150 mM NaCl. The A1 protein and
aptamer ARC1172 were mixed at a molar ratio of 1: 1.4.
Crystals were obtained with the hanging drop vapor diffusion technique by
mixing 1 ml A1-ARC1172 solution with 1 ml reservoir solution at 20 degrees.
Two different crystal forms were grown in reservoir solution I (25%
Figure 6. Analysis of VWF A1-ARC1172
Binding
(A–D) Microtiter plates were coated with rabbit
anti-VWF (A–C) or monoclonal anti-VWF CK
62-12 (D) as described in Experimental Proce-
dures. Error bars represent standard error.
(A) Shear stress does not affect ARC1172-VWF
binding. VWF (5 mg/ml) and biotin-ARC1172 (5,
2.5, 1.25, 0.625, 0.3125, 0.155, 0.0775 nM) were
mixed and treated without (squares) or with (trian-
gles) shear stress for 2 min (Zhang et al., 2007)
before assessment of binding. Values ± standard
deviation (SD)) for maximal binding (Bmax) and KD
are tabulated.
(B) Binding of biotin-ARC1172 (2.5 nM) to VWF (5
mg/ml) was similar without (triangles) or with
(squares) monoclonal antibody 1C1E7 Fab
(34 nM), which binds VWF domain D3 and
enhances VWF binding to GPIba with an EC50 of
<40 nM (Ulrichts et al., 2006). Values ± SD for
Bmax and KD are tabulated.
(C) 1C1E7 Fab did not inhibit biotin-ARC1172
(2 nM) binding to VWF (0.5 mg/ml).
(D) Recombinant VWF A1 (squares) or unbiotiny-
lated ARC1172 (triangles) inhibited the binding of
biotin-ARC1172 (1 nM) to VWF (5 mg/ml).
PEG3350, 0.16 M NaF) and solution II (containing
0.2 M NH4Ac, 0.1 M NaAc pH4.6, 30% PEG4000)
and belong to space group P212121 (structure I)
and P21212 (structure II), respectively.
The crystals were flash-cooled by plunging into
liquid nitrogen after soaking in cryoprotectant of
20% glycerol in corresponding handing drop solu-
tion for 1 min. The diffraction data from a single crystal were then collected at
the Advanced Photo Source (APS) using 0.9 A˚ wavelength X-rays collected on
an ADSL detector or an in-house diffractometer with a R-AXIS IV imaging plate
detector (Rigaku) and processed using HKL2000 software (Otwinowski and
Minor, 1997).
Structural Calculation and Refinement
Molecular replacement was performed with Molrep (Vagin and Teplyakov,
1997) to determine the initial phases using the coordinates of VWF A1 domain
at a resolution of 1.8 A˚ (Protein Data Bank ID number 1IJB) and generates
traceable electronic density for the aptamer in structure I (space group
P212121). Structure II (space group P21212) was then solved using the newly
generated coordinates for structure I. Models were built using COOT (Emsley
and Cowtan, 2004) and refined in Refmac (Murshudov et al., 1997) and Phenix
(Zwart et al., 2008) with TLS parameters (Winn et al., 2001). The structures
were analyzed using Nucplot (Luscombe et al., 1997), MolProbity (Davis
et al., 2007), and CCP4 (1994). A summary of diffraction data and refinement
statistics is shown in Table 1. Molecular graphics figures were prepared with
PyMOL (DeLano Scientific, Palo Alto, CA).
VWF A1-ARC1172 Binding Assay
Biotin-ARC1172 was synthesized with a biotin moiety at the 50-end. Microtiter
plates were coated with 100 ml anti-VWF polyclonal antibodies (Dako 082,
3.1 mg/ml) or anti-VWF CK monoclonal antibody (CK62-12, 13 mg/ml) or
directly coated with VWF (Haematologic Technologies Inc. Essex Junction,
VT). Plates were blocked with 200 ml T-PBS (0.1% Tween 20 in phosphate-
buffered saline) containing 3% bovine serum albumin, and washed three times
with T-PBS. Solutions of VWF and biotin-ARC1172 with any other indicated
additions were incubated in microtiter wells at room temperature for 30 min.
The plates were washed three timeswith T-PBS and incubated with 100 ml/well
of HRP-conjugated streptavidin (1:2500) in T-PBS for 15 or 30 min. Unbound1482 Structure 17, 1476–1484, November 11, 2009 ª2009 Elsevier Ltd All rights reserved
Structure
Structure of VWF A1 in Complex with a DNA Aptamerstreptavidin was removed by washing three times with T-PBS and the bound
HRP-streptavidin signals was detected by incubation with 100 ml/well of
freshly made TMB (Pierce). Reactions were stopped with 2 M H2SO4 before
reading absorbance at 450 nm.
In some cases, mixtures of VWF and biotin-ARC1172 were subjected to fluid
shear stress before addition to microtiter plates coated with anti-VWF. Shear
stress was applied to reactions essentially as described (Zhang et al., 2007).
Briefly, reactions were incubated at room temperature on a bench-top vortex
device (Vortex-Genie 2, Scientific Industries, Inc., Bohemia, NY) at maximal
speed (3200 rpm) for the indicated time.
ACCESSION NUMBERS
Coordinates and structure factors for both crystal forms of VWF A1-ARC1172
have been deposited in the RCSB Protein Data Bank with accession codes
3HXQ and 3HXO.
SUPPLEMENTAL DATA
Supplemental Data include seven figures and three tables and can be
found with this article online at http://www.cell.com/structure/supplemental/
S0969-2126(09)00379-7.
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